Ageing and stress have been identified as potential contributors to inflammation. While stress-related inflammation often subsides on its own, there are instances where it evolves into a chronic condition. Prolonged or chronic inflammation can give rise to severe health issues, causing irreversible damage to the body. SENEX aims to disrupt the cycle of chronic inflammation through the utilization of AAV-mediated gene therapy. Initially, the company is concentrating its efforts on addressing Pulmonary Arterial Hypertension and Osteoarthritis.
Company Details
- Employees
- 3
- Address
- 94th Street, New York,ny 10025,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.senextx.com
- HQ
- New York, NY
Senex Therapeutics Questions
Senex Therapeutics's website is http://www.senextx.com
Senex Therapeutics's LinkedIn profile is https://www.linkedin.com/company/senex-tx
Senex Therapeutics has
3 employees.
View email and phone details for 3
employees at Senex Therapeutics.
Senex Therapeutics's industry is
Biotechnology Research
Senex Therapeutics's top competitors are
Frezent Biological Solutions,
Prevail Therapeutics,
Nest Catalyst Ventures,
Aveta.life,
Apertura Gene Therapy,
Foley & Lardner Llp,
Alloy Therapeutics, Inc.,
Khepri Animal Health,
Biotech Xyz,
Neurodex.
Senex Therapeutics's categories are Biotechnology Research
